Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 12,398.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2016 17:30

RNS Number : 9044W
AstraZeneca PLC
29 April 2016
 

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

 

Results of Annual General Meeting held on 29 April 2016

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015

 

924,514,473

99.61

3,665,459

0.39

928,179,932

73.40%

8,998,621

2

To confirm dividends

 

933,191,043

99.69

2,915,972

0.31

936,107,015

74.03%

1,071,537

3

To re-appoint KPMG LLP, London as Auditor

 

929,918,594

99.56

4,151,154

0.44

934,069,748

73.87%

3,108,804

4

To authorise the Directors to agree the remuneration of the Auditor

 

934,984,319

99.89

988,556

0.11

935,972,875

74.02%

1,204,865

5a

To re-elect Leif Johansson as a Director

 

861,678,834

94.69

48,321,545

5.31

910,000,379

71.96%

27,177,942

5b

To re-elect Pascal Soriot as a Director

 

935,167,473

99.93

697,471

0.07

935,864,944

74.01%

1,342,796

5c

To re-elect Marc Dunoyer as a Director

 

931,875,086

99.58

3,920,615

0.42

935,795,701

74.00%

1,380,982

5d

To re-elect Cori Bargmann as a Director

 

935,157,654

99.93

635,873

0.07

935,793,527

74.00%

1,384,110

5e

To re-elect Geneviève Berger as a Director

 

935,199,102

99.93

622,099

0.07

935,821,201

74.00%

1,356,436

5f

To re-elect Bruce Burlington as a Director

 

933,026,505

99.70

2,762,355

0.30

935,788,860

74.00%

1,389,088

5g

To re-elect Ann Cairns as a Director

 

933,220,149

99.72

2,618,183

0.28

935,838,332

74.01%

1,339,989

5h

To re-elect Graham Chipchase as a Director

 

919,686,570

98.97

9,526,012

1.03

929,212,582

73.48%

7,965,366

5i

To re-elect Jean-Philippe Courtois as a Director

 

933,177,891

99.72

2,593,420

0.28

935,771,311

74.00%

1,406,637

5j

To re-elect Rudy Markham as a Director

 

923,984,532

98.74

11,766,347

1.26

935,750,879

74.00%

1,427,442

5k

To re-elect Shriti Vadera as a Director

 

927,479,182

99.11

8,287,726

0.89

935,766,908

74.00%

1,410,552

5l

To re-elect Marcus Wallenberg as a Director

 

870,828,312

95.76

38,511,577

4.24

909,339,889

71.91%

27,837,158

6

To approve the Annual Report on Remuneration for the year ended 31 December 2015

836,396,151

89.61

96,959,428

10.39

933,355,579

73.81%

3,822,290

7

To authorise limited EU political donations

 

908,106,542

97.83

20,185,176

2.17

928,291,718

73.41%

8,886,009

8

To authorise the Directors to allot shares

 

849,809,843

90.97

84,303,774

9.03

934,113,617

73.87%

3,064,122

9

To authorise the Directors to disapply pre-emption rights

 

922,425,478

98.82

11,009,374

1.18

933,434,852

73.82%

3,742,888

10

To authorise the Company to purchase its own shares

 

926,166,577

98.96

9,722,078

1.04

935,888,655

74.01%

1,289,613

11

To reduce the notice period for general meetings

 

829,946,353

88.85

104,116,202

11.15

934,062,555

73.87%

3,115,081

 

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

29 April 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUGACUPQGAB
Date   Source Headline
1st Sep 20203:00 pmRNSTotal Voting Rights
1st Sep 20207:00 amRNSImfinzi approved in EU for small cell lung cancer
1st Sep 20207:00 amRNSFarxiga reduces CKD progression and risk of death
25th Aug 20207:00 amRNSPh I trial begins for COVID-19 monoclonal antibody
21st Aug 20207:00 amRNSImfinzi approved in Japan for SCLC
18th Aug 20207:00 amRNSImfinzi US Priority Review; four-week, fixed dose
4th Aug 20207:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20203:00 pmRNSTotal Voting Rights
30th Jul 20207:25 amRNSTagrisso US BTD for EGFRm adjuvant lung cancer
30th Jul 20207:18 amRNSAZN: H1 2020 results
29th Jul 20207:00 amRNSBoard Committee Changes
28th Jul 20207:00 amRNSFarxiga DAPA-CKD trial met all endpoints
27th Jul 20207:10 amRNSCalquence receives positive CHMP opinion for CLL
27th Jul 20207:05 amRNSImfinzi recommended for EU approval in SCLC
27th Jul 20207:00 amRNSAstraZeneca enters collaboration in oncology
24th Jul 20207:00 amRNSBreztri Aerosphere approved in the US for COPD
22nd Jul 20203:00 pmRNSHolding(s) in Company
22nd Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
20th Jul 20202:41 pmRNSCOVID-19 vaccine Phase I/II showed immune response
16th Jul 20207:00 amRNSDirector Declaration
9th Jul 20207:00 amRNSBrilinta granted US FDA Priority Review for stroke
8th Jul 20207:00 amRNSLynparza approved in the EU for pancreatic cancer
1st Jul 20203:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSSelumetinib granted Japan orphan drug designation
17th Jun 20203:03 pmRNSHolding(s) in Company
17th Jun 20203:00 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSAgreement to Supply Europe with COVID-19 Vaccine
11th Jun 20207:00 amRNSEMTN Programme Routine Technical Update
1st Jun 20203:00 pmRNSBlock listing Interim Review
1st Jun 20203:00 pmRNSTotal Voting Rights
1st Jun 20207:00 amRNSLynparza EU CHMP opinion in pancreatic cancer
1st Jun 20207:00 amRNSBrilinta obtains additional US approval
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:35 pmRNSPrice Monitoring Extension
29th May 20201:00 pmRNSImfinzi sustained overall survival in CASPIAN
29th May 20201:00 pmRNSEnhertu DESTINY-Gastric01 results from ASCO 2020
29th May 20207:00 amRNSTagrisso unprecedented adjuvant lung cancer data
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.